1 – 8 of 8
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
(
- Contribution to journal › Article
- 2014
-
Mark
32p * biomarkers and molecular subtypes in primary breast tumors and metastases: associations with liver metastases and outcome.
(
- Contribution to journal › Article
- 2013
-
Mark
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
(
- Contribution to journal › Article
-
Mark
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
(
- Contribution to journal › Article
- 2012
-
Mark
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
(
- Contribution to journal › Article
- 2011
-
Mark
Inactivation of promoter 1B of APC causes partial gene silencing: evidence for a significant role of the promoter in regulation and causative of familial adenomatous polyposis
(
- Contribution to journal › Article
- 2000
-
Mark
Prognosis and clinical presentation of BRCA2-associated breast cancer
(
- Contribution to journal › Article